ASCO GU 2026

New classifications and imaging modalities in Prostate…

Encouraging new data in Prostate cancer

EZH2 oral molecule to enhance ARPI

T-cell engager - first in human

Radium-223 + Enzalutamid

Actinium radioligand therapy

Prolonged PSA declines with normalization of…

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

T-Cell-Engager

New Mode of Action in mCRPC

Benefit of PARPi + ABI combination

Neoadjuvant therapy after molecular biopsy testing

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Balancing efficacy and toxicity: the challenge in high…

Advances in the Adjuvant Treatment of RCC

Upcoming new standard for adjuvant RCC

Real World Data - RCC

Combination therapy in adjuvant RCC

New second-line option in mRCC

HIF based combination are here to stay

Long‑term effects of adjuvant therapy

Treatment after immunotherapy in aRCC: always a complex…

Equilibrar eficacia y toxicidad: el desafío en el ccRCC…

Important steps towards biomarker driven treatment of…

Closing the gap for platin eligibility

BCG plus CPI for NMIBC - do the benefits outweigh the…

A new class of drug in luminal UC

New machanism of action in pts with UC

ctDNA testing: Who, how and how often?

Perioperative EV + P - the new standard?!

EV+P new SOC in MIBC

MIBC - time for a historic paradigm shift?

Promising data - how to stratify the patients for the…

New perioperative standard for MIBC

Urinary ctDNA vs. plasma ctDNA

ctDNA dynamics in the IMvigor011 trial

ctDNA from plasma and urine in MIBC

Rethinking the use of HER2neu in routine clinical…

Perioperative EV+Pembrolizumab in MIBC

Cáncer de vejiga músculo-invasivo: ¿es hora de un…

Une nouvelle classe de médicaments pour le carcinome…

EV + P : nouveau standard de traitement pour le TVIM